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The role of radiotherapy is well established in combined modality programs for early stage
Hodgkin’s lymphoma, but still debated with regards to late toxicity issues. Modern radio-
therapy prescribing attitudes include lower doses and smaller fields, together with the
implementation of sophisticated and dedicated delivery techniques. Aim of this review is
to  briefly discuss the current role of radiotherapy in this field and the potential future devel-Keywords:
Hodgkin’s lymphoma
Radiotherapy
Combined modality therapy
opments. Major trials conducted in recent years in early stage Hodgkin’s lymphoma are
critically reviewed and discussed with a focus on radiotherapy-related issues and with an
attention to current treatment options by a “young” radiation oncologists’ perspective.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
totally replaced right now with a combination of short-1.  Background
For patients with Hodgkin’s lymphoma (HL) in any stage, the
primary goal of therapy is cure. In recent studies, the survival
rate in early stages has consistently been 90% or higher. In
studies with long-term follow-up, treatment-related compli-
cation deaths exceed the number of cancer-related deaths.
The frequency of late complications is dependent on the
treatment used. Radiation-related cardiac disease (coronary
artery disease, myocardial injury, valvular disease, pericardial
fibrosis) and second malignancies (breast and lung cancer)
may occur many  years after thoracic irradiation and are
dependent on radiation doses and volumes. The risk of late
complications after chemotherapy (cardiac toxicity, second
malignacies) appears to be dependent on the type of drugs
∗ Corresponding author at: Radiation Oncology, Department of Oncolog
Tel.:  +39 0116705352.
E-mail address: andreariccardo.filippi@unito.it (A.R. Filippi).
1507-1367/$ – see front matter © 2012 Greater Poland Cancer Centre. Publish
http://dx.doi.org/10.1016/j.rpor.2012.05.003prescribed (alkylating agents, anthracycline, bleomycin) and
on the cumulative dose. Treatment strategies in HL changed
therefore dramatically during recent years, with current clin-
ical protocols focusing, especially on early stage HL, on
minimizing the intensity of treatment to avoid late potentially
fatal toxic effects, without the risk of lowering overall survival
rates.
1.1.  Radiotherapy  in  the  cure  of  Hodgkin’s  lymphoma
For many  decades, the optimal and standard treatment
for early stage HL was extended field radiotherapy (EF-RT),y, University of Torino, Via Genova 3, 10126 Torino, Italy.
term chemotherapy with involved field radiotherapy (IF-RT).
The evolution of effective treatments for early stage HL is
best exemplified by the successive randomized trials of the
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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tation (bulky disease, multiple involved sites, high ESR values),reports of practical oncology and 
erman Hodgkin’s Study Group (GHSG), as discussed in a
aper by Hans Theodor Eich and Rolf-Peter Müller in 2007.1
he first protocol dealing with a radiotherapy-related end-
oint was the HD4 trial, designed in the early eighties
1988–1994). The major aim of HD4 was to show whether the
adiation dose to the non-involved lymphatic regions could be
educed while maintaining effective tumour control. This trial
as conceived as an effort towards a further improvement of
esults obtained in 1962–1984 by the Stanford group in early
tages with radiotherapy, showing complete remission rates of
00% and recurrence free survival of 80% in stages IA, IIA and
IB without large mediastinal tumour (excellent results uncon-
rmed by other groups). In HD4, patients in stage I or II without
isk factors (large mediastinal mass, extranodal extension,
assive spleen involvement, >3 lymph node areas, high ESR)
ere randomized between standard treatment consisting of
0 Gy EF-radiotherapy (arm A) and 30 Gy EF-radiotherapy plus
dditional 10 Gy to the IF (arm B). Staging laparotomy was
bligatory in this protocol. The results showed no statisti-
ally significant differences in recurrent free survival (RFS) and
verall survival (OS) between the two treatment arms, but the
verall recurrence rate approached 20%, as reported by the
tanford studies. Due to an effective salvage therapy (poly-
hemotherapy), RFS after seven years went up to 80% and the
verall survival was 93%.2 The pattern of relapse in this study
howed interesting results, with the majority of recurrences
ocumented outside high dose radiation fields, probably due
o errors in initial staging or in radiotherapy prescription. Due
o the crucial importance of good quality radiotherapy in such
tudies, German Hodgkin Study Group promoted the creation
f a task force for radiotherapy quality assurance, and for all
atients enrolled in the study a treatment plan was given by
he radiotherapy reference centre based on the documenta-
ion of the disease extension on case report forms (CRF), and
fter completion of the EF radiotherapy, simulation and veri-
cation films of every individual patient as well as treatment
ata analysis by an expert panel. This retrospective quality
ontrol study showed that deviations of radiation treatment
ortals and radiation doses from prospective treatment pre-
criptions were unfavourable prognostic factors for patients
ith early-stage HL.3 Next research step of GHSG was a trial
esigned to keep the approach of low-dose EF of HD4 while try-
ng to eradicate microscopic disease with chemotherapy and
mproving Relapse-Free Survival. In HD7 (1994–1998), patients
ere randomized between radiotherapy alone (30 Gy EF + 10 Gy
F) (arm A) or upfront 2 cycles ABVD followed by radiotherapy
30 Gy EF + 10 Gy IF) (arm B) for early stages PS IA, IIA, IIB with-
ut risk factors. Staging laparotomy was not obligatory and
he spleen was irradiated with 36 Gy in both treatment arms.
t 7 years, there was no difference between treatment arms in
erms of complete response rate (arm A: 95%, arm B: 94%) or
S (arm A: 92%, arm B: 94%; P = 0.43). However, freedom from
reatment failure (FFTF) was significantly different with 67%
n arm A and 88% in arm B (P ≤ 0.0001). This was mainly due
o significantly more  relapses after EF-radiotherapy only (arm
: 22%; arm B: 3%).4
HD10 trial (1998–2002) was designed to eliminate the EF
pproach, including IF only and with the primary aim of
educing acute and long term toxicities while maintaining
ptimal tumour control. This trial also incorporated results oftherapy 1 7 ( 2 0 1 2 ) 246–250 247
major studies published in the nineties by North-American,
European/French and Italian Groups, focusing on the role
of chemotherapy and including the “involved fields” con-
cept. All these studies showed a complete equivalence for
the brief chemotherapy + IF vs. EF alone or chemotherapy + EF
approach. As well pointed out by HT Eich and RP Muller,
the HD10 trial represents a very decisive step, since irradia-
tion was performed as IF radiotherapy in all treatment arms.
The HD10 is the first trial designed to investigate the opti-
mal  intensity of chemotherapy and radiotherapy. The whole
treatment strategy is based upon a selection of patients with
favourable prognostic factors, in whom reduced treatment
intensity should offer very good results in terms of disease
control while reducing toxicity. Therefore, patients in stages I
or II without risk factors (no bulky disease, less than 4 involved
sites, low ESR values) were randomized in a four-arm study
between an IF-radiotherapy dose of 30 Gy versus 20 Gy and 2
versus 4 cycles of ABVD. To make sure that IF-radiotherapy
was performed exactly according to the RT-prescriptions of
the protocol, an extensive quality assurance program was
performed. Results of HD10 were published in 20105: the
2 chemotherapy regimens did not differ significantly with
respect to freedom from treatment failure (P = 0.39) or over-
all survival (P = 0.61). At 5 years, the rates of freedom from
treatment failure were 93.0% (95% confidence interval [CI],
90.5–94.8) with the four-cycle ABVD regimen and 91.1% (95%
CI, 88.3–93.2) with the two-cycle regimen. When the effects of
20-Gy and 30-Gy doses of radiation therapy were compared,
there were also no significant differences in freedom from
treatment failure or overall survival (P = 0.61). HD10 demon-
strated that treatment with two cycles of ABVD followed by
20 Gy of involved field radiation therapy is as effective as,
and less toxic (acute toxicity) than, four cycles of ABVD fol-
lowed by 30 Gy of involved-field radiation therapy. A parallel
but different study is ongoing in early stage favourable and
unfavourable patients, designed by EORTC/GELA/IIL, the H10
trial, comparing a treatment strategy based on interim (after
2 ABVD cycles) 18F-fluorodeoxyglucose positron emission
tomography (FDG-PET) and on the introduction of an inno-
vative radiotherapy concept, the so-called “Involved Nodes
Radiation Therapy” (INRT). This trial is now closed and final
results will be available in next years. Two major trials investi-
gating the role of chemotherapy alone (ABVD) were published
some years ago, showing that CT alone is a feasible option for
patients with non-bulky early-stage Hodgkin’s lymphoma.6,7
An increased freedom from progression was shown for the
combined-modality arms when compared with chemother-
apy alone (86% vs. 81% and 93% vs. 87%, respectively), and
since current recommended approaches towards relapse after
primary therapy include autologous stem cell transplant, the
current dilemma facing clinicians is whether all patients
should be irradiated to prevent progression in 5–6% of cases
or whether it is justified to withhold radiation, knowing
that patients with progression will be referred to high-dose
chemotherapy.
For patients with unfavourable early stage disease presen-the treatment approach was similar but results should be
evaluated separately; all major trials investigated a combi-
nation of at least 4 chemotherapy cycles (however 6 cycles
248  reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 246–250
Table 1 – Temporal evolution of radiation therapy for Hodgkin’s lymphoma.
RT approach Years Dose Technique Tools Facilities
EFRT 1960–1990 40–44 Gy 2D RT 2D planning Cobalt Units; first LINACs
IFRT 1995 to present 30–36 Gy
3DCRT Forward planning LINACs with cerrobend blocks
Static-IMRT Inverse planning LINACs with MLC
IFRT-INRT 2008 to present 20–30 Gy
3DCRT Forward planning LINACs with MLC
Static-IMRT Inverse planning
Arc-therapy Biologic optimization
Tomotherapy Multimodality imaging IGRT/dynamic IMRT dedicated LINACsin the majority of treatment arms) + EF or IF radiotherapy
(EORTC H7U, EORTC/GELA H8U, EORTC/GELA H9U), showing
that the IF approach is safe and equivalent to EF and that,
globally, the results of combined modality therapy are infe-
rior to those in favourable stages, with FFTF rates in the range
of 84–94%. In this setting, a reduction in treatment intensity
did not demonstrate any equivalence in terms of disease con-
trol. The recently published GHSG HD11 trial8 was designed to
specifically investigate this issue. With a total of 1395 patients
included, BEACOPP was more  effective than ABVD when fol-
lowed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI,
0.1–11.3%), however, there was no difference between BEA-
COPP and ABVD when followed by 30 Gy of IFRT (5-year FFTF
difference, 1.6%; 95% CI, −3.6% to 6.9%). Similar results were
observed for the radiotherapy question: after 4 cycles of BEA-
COPP, 20 Gy was not inferior to 30 Gy (5-year FFTF difference,
−0.8%; 95% CI, −5.8% to 4.2%), whereas inferiority of 20 Gy
cannot be excluded after four cycles of ABVD (5-year FFTF dif-
ference, −4.7%; 95% CI, −10.3% to 0.8%). At the moment, in
unfavourable early stage HL, 4 ABVD followed by 30 Gy IF-RT
continues to represent a standard clinical approach (waiting
for the final results of HD17 on 2 ABVD + 2 BEACOPP + IFRT
30 Gy).
Table 1 summarizes the time-trend in radiotherapy
changes in Hodgkin’s lymphoma in recent years.
1.2.  Open  issues  and  future  developments
As briefly discussed, currently radiotherapy in early favourable
and unfavourable presentations is an essential component of
the standard treatment, as confirmed by a recent study by the
Cochrane Collaboration Group on the outcome of combined
modality therapy vs. chemotherapy alone (primary endpoint
overall survival).9 This important message is incorporated in
therapeutic indications within international guidelines (such
the ones from NCCN or ESMO) where combined modality
treatment still represents a mainstay option as HL therapeutic
strategy.10,11 Globally and independently from the treatment
approach, the issue of late toxicity still remains crucial. In
almost all trials with long-term follow-up, the number of
patients who die from other causes exceeds the number of
patients dying from lymphoma. Second malignancies and
fatal cardiac events are the main causes of death in a cohort
of patients who  presently show a relapse-free survival prob-
ability of approximately 90%. Due to the established toxicity
of extended field radiotherapy, especially in patients receiv-
ing mediastinal irradiation, several studies were designed inDose painting
IGRT
recent years in order to decrease toxicity either by reducing
or avoiding radiotherapy, trying to show a superior overall
survival rate in chemotherapy only arms secondary to a reduc-
tion of RT-related deaths. An example of this research strategy
is the already cited NCIC HD6 trial, designed with the aim
of comparing chemotherapy only (4–6 ABVD cycles) to RT
only or with 2 ABVD cycles (according to risk groups), with
subtotal nodal irradiation of 35 Gy. A New England Journal of
Medicine special issue dedicated to haematology-related stud-
ies was edited in December 2011 concurrently with the 2011
ASH Annual Meeting, and the main paper of this issue is the
final report of this study.12 Results were very disappointing
for the radiotherapy arm. The median length of follow-up was
11.3 years. At 12 years, overall survival rate was 94% among
those receiving ABVD alone, as compared with 87% among
those receiving subtotal nodal radiation therapy. The rates of
freedom from disease progression were 87% and 92% in the
two groups, respectively, and the rates of event-free survival
were 85% and 80%, respectively. Among the patients randomly
assigned to ABVD alone, 6 died from Hodgkin’s lymphoma or
an early treatment complication and 6 died from other causes;
among those receiving radiation therapy, 4 deaths were related
to Hodgkin’s lymphoma or early toxic effects from the treat-
ment and 20 were related to other causes. An obvious critical
point in this trial is that the subtotal nodal radiation ther-
apy is no longer employed and radiation induced toxicity is
expected to be less relevant in the future with modern radio-
therapy strategies and techniques (IF-RT, IN-RT, IMRT,  IGRT,
CT-PET-driven contouring) employed in recent years. Com-
ments in the Editorial by David J. Straus13 are focused on
the final demonstration that ABVD only is probably a better
approach, taking into account that efficient salvage thera-
pies can compensate the higher relapse rate of chemotherapy
only. In this complex scenario, as briefly shown, many  other
groups tested different strategies, based on toxicity reduction
by means of radical modification of radiotherapy doses and
volumes. These approaches are based on the assumption that
late toxicity data on radiation therapy from historical trials
cannot be fully translated to current protocols, and probably
it is unrealistic that every kind of radiation therapy strategy is
harmful at the same level. A new radiation oncology question,
such as the possibility of a further reduction of radiation fields
compared to the classical involved field concept, limiting irra-
diation only to the single nodal station involved by the disease
at diagnosis (IN-RT) rather than the whole anatomical region,
is under investigation by the already cited EORTC-GELA-IIL
H10 trial and by the ongoing GHSG HD17 trial, quite recently
radio
o
b
n
t
e
s
a
o
s
T
e
t
d
k
p
i
A
b
m
a
r
b
m
d
m
c
h
m
i
b
b
w
a
d
i
i
t
(
a
b
I
s
d
t
u
y
d
t
i
c
a
fi
A
i
s
m
c
p
i
rreports of practical oncology and 
pened to accrual. Below the INRT concept, the technological
reak-troughs in radiation oncology led to the employment of
ew treatment techniques such as Intensity Modulated Radio-
herapy (IMRT) also in the field of hemato-oncology.14 The
xtended fields of the past limited the radiation technique to
imple parallel-opposed anterior-posterior fields, but reduced
nd better defined radiation volumes allow for the utilization
f more  conformal radiation therapy, based on more  con-
istent imaging and advanced radiation delivery techniques.
hese recently introduced radiotherapy planning and deliv-
ry techniques have already demonstrated better sparing of
he heart, coronary arteries, lung and breast. The achievable
ose reduction can be protective for normal tissues for well
nown dose-related radiotherapy late effects such as radiation
neumonitis/fibrosis or coronary artery disease, with an open
ssue regarding the impact on secondary malignancy risk.15,16
s pointed out by Paumier et al. in 2011, the optimal com-
ined modality approach in early stage HL should encompass
inimal chemotherapy and subsequent minimal radiother-
py with simultaneous effort to decrease late complication
ate without jeopardizing clinical outcome results.17 It has
een demonstrated that the risk of radiation-induced second
alignancies (particularly breast and lung cancer) is linearly
ependent on delivered dose and becomes of a detectable
agnitude at 20–30 Gy.18 Both IMRT  technique and INRT con-
ept are able to reduce the volume of normal tissue receiving
igh doses and consequently might reduce the risk of second
alignancies due to ‘high doses’ and ‘extended fields’. Histor-
cally, the shrinkage of radiation fields from EF-RT to IF-RT has
een shown to decrease the risk of second cancers, as reported
y De Bruin et al.19 Hence, this effect might be postulated also
henever shifting from IF-RT to IN-RT is performed. However,
s a matter of fact, IMRT  techniques increase low-radiation
ose bath to normal tissues. The clinical implications of this
ssue in terms of carcinogenetic risk are difficult to assess, as
s the magnitude of this effect. Some well-known determinis-
ic dose-related effects of radiotherapy, such as heart diseases
mainly coronary arteries disease, but also myocardic dam-
ge leading to late heart failure) or hypothyroidism, should
e drastically reduced with low-dose INRT (eventually with
MRT planning and further reduction in normal tissues expo-
ure); regarding this issue, apart from some very interesting
osimetric studies,20,21 we currently do not have enough data
o clearly demonstrate a clinical benefit. Joachim Yahalom
nderlined in his recent paper that although it will take more
ears of careful follow-up of patients in randomized studies to
isplay the full magnitude of risk tapering by current reduc-
ion of radiation fields and doses, recent data suggest that this
s likely to be the case.22
As young Radiation Oncologists involved in the multidis-
iplinary Lymphoma Team, we assume that these different
pproaches to the issue of late toxicity (no RT at all, modi-
ed low-toxicity RT) are not necessarily mutually exclusive.
 consistent effort in trying to understand if new RT modal-
ties are able to reduce the negative impact on survival of
econd malignancies and cardiac events should be done by
onitoring late toxicity in clinical practice and not only in
linical trials, and an effort in optimizing radiation therapy
lanning and delivery with the primary endpoint of reduc-
ng toxicity should be implemented. In a parallel view, newtherapy 1 7 ( 2 0 1 2 ) 246–250 249
combined modality protocols such as, for example, ABVD x
2 cycles + IFRT-INRT 20 Gy in favourable presentations, should
be prospectively tested against chemotherapy only, with over-
all survival as primary endpoint. Currently, it is very difficult
to assess whether a low-dose, small-volume RT + 2 cycles
of chemotherapy combination is more  toxic than 4–6 ABVD
cycles (in the Canadian trial 10 out of 196 patients in the CT-
only arm developed a second malignancy and 16 a cardiac
event, with 6/12 non Hodgkin’s related deaths), even if the
two options are likely to be similar in terms of disease con-
trol (comparing global results of GHSG HD10 study and the
chemotherapy only arm of NCIC HD6 trial, with OS rates of
respectively 95% an 94% and FFS rates of respectively 87.1%
and 87% at 8 years). The rate of second malignancies in the
HD10 study was globally 4.6%, without significant differences
between treatment arms, but the follow-up time is probably
too short to be conclusive, as we  are not certain that the low-
dose approach will be less carcinogenetic. We also do not know
about long-term results of INRT. To conclude, in our opinion
the majority of patients should be possibly included in clin-
ical trials; outside these studies, combined modality should
remain a standard therapeutic approach, as specified in sev-
eral International Guidelines, with a thoughtful attention on
late effects and on the possibilities of lowering cardiac toxicity
and probable second malignancy risk with low-dose programs
for favourable patients and/or with the employment of new RT
techniques in critical presentations.
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